美国食品和药物管理局批准Ryoncil治疗儿童移植后严重疾病。 The U.S. FDA approves Ryoncil for treating a severe condition in children post-transplant.

美国FDA批准了Ryoncil (remestemcel-L),这是美国首个中细胞干细胞 (MSC) 治疗方法,用于治疗2个月及以上儿童的类固醇耐药急性移植对宿主疾病 (SR-aGVHD). The U.S. FDA has approved Ryoncil (remestemcel-L), the first mesenchymal stromal cell (MSC) therapy in the U.S., for treating steroid-refractory acute graft-versus-host disease (SR-aGVHD) in children aged 2 months and older. 在第三阶段试验中,70%的病人在第28天前表现出全面反应。 In a Phase 3 trial, 70% of patients showed an overall response by Day 28. 由Mesoblast开发的治疗方法来自骨髓细胞,通过抑制细胞活化和减少炎症而发挥作用。 The therapy, developed by Mesoblast, is derived from bone marrow cells and works by inhibiting T cell activation and reducing inflammation. 常见的副作用包括感染、发烧和高血压。 Common side effects include infections, fever, and hypertension.